Explore: The Journal of Science and Healing
Volume 3, Issue 1 , Pages 16-22 , January 2007

The Homeopathic Antiarthitic Preparation Zeel comp. N: A Review of Molecular and Clinical Data

  • Heinz Birnesser, MD

      Affiliations

    • Klinik für Sportorthopädie/Sporttraumatologie, Universitätsklinikum Freiburg, Freiburg, Germany
    • Corresponding Author InformationCorresponding Author. Address: Klinik für Sportorthopädie/Sporttraumatologie, Universitätsklinikum Freiburg, Germany
    • ,
  • Pelle Stolt, PhD

      Affiliations

    • Maglia Rotta, Basel Switzerland

References 

  1. Homöopathisches Arzneibuch 2000 (German Homeopathic Pharmacopoeia). Stuttgart: Medpharm GmbH Scientific Publishers, 2003.
  2. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2003;62:501–509
  3. Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one?. J Rheumatol. 2001;28:2375–2382
  4. Brune K. Safety of anti-inflammatory treatment–new ways of thinking. Rheumatology. 2004;43:i16–i20
  5. Raisz LG. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage. 1999;7:419–421
  6. Hudson N, Balsitis M, Everitt S, Hawkey C. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal antiinflammatory drugs. Gut. 1993;34:742–747
  7. Bisgaard H. Leukotrienes and prostaglandins in asthma. Allergy. 1984;39:413–420
  8. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclo-oxygenase and 5-lipoxygenase (A new avenue in anti-inflammatory therapy?). Biochem Pharmacol. 2001;62:1433–1438
  9. Laufer S, Tries S, Agustin J, Dannhardt G. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforsch. 1994;44:629–636
  10. Celotti F, Durand T. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins Other Lipid Mediat. 2003;71:147–162
  11. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000;85:169–182
  12. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18–24
  13. Safety concerns associated with over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use: 2004. Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/drug/analgesics/SciencePaper.pdf. Accessed August 15, 2006.
  14. Lyss G, Schmidt TJ, Merfort I, Pahl HL. Helenalin, an antiinflammatory sesquiterpene lactone from Arnica selectively inhibits transcription factor NF-kappaB. Biol Chem. 1997;378:951–961
  15. Klaas CA, Wagner G, Laufer S, et al. Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica Flowers. Planta Med. 2002;68:385–391
  16. Godowski KC. Antimicrobial action of sanguinarine. J Clin Dent. 1998;1:96–101
  17. Kurokawa M, Basnet P, Oshugi M, Hozumi T, Kadota S, Namba T. Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica in vitro and in vivo. J Pharmacol Exp Ther. 1999;289:72–78
  18. Lin YM, Anderson H, Flavin MT, Pai YH, Mata-Greenwood E, Pengsuparp T. In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod. 1997;60:884–888
  19. Saxena G, McCutcheon AR, Farmer S, Towers GH, Hancock RE. Antimicrobial constituents of Rhus glabra. J Ethnophamacol. 1994;42:95–99
  20. Tunon H, Olavsdotter C, Bohlin L. Evaluation of anti-inflammatory activity of some Swedish medicinal plants (Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis). J Ethnopharmacol. 1995;48:61–76
  21. Tunon H, Olavsdotter C, Bohlin L. Evaluation of antiinflammatory activity of some Swedish medicinal plants (Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis). J Ethnopharmacol. 1995;48:61–76
  22. Kurz B, Lemke AK, Fay J, Pufe T, Grodzinsky AJ, Schunke M. Pathomechanisms of cartilage destruction by mechanical injury. Ann Anat. 2005;187:473–485
  23. Yamada H, Watanabe K, Saito T, et al. Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol. 1999;26:654–662
  24. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol. 1998;2:466–471
  25. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998;21:75–80
  26. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 1996;3:895–904
  27. In:  Hawkes SP,  Edwards DR,  Khokha R editor. Inhibitors of Metalloproteinases in Development and Disease. Lausanne, Switzerland: Harwood; 1997;
  28. Jaggi R, Wurgler U, Grandjean F, Weiser M. Dual inhibition of 5-lipoxygenase/cyclooxygenase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability. Inflamm Res. 2004;53:150–157
  29. Blasey HD, Lundstrom K, Tate S, Bernard AR. Recombinant protein production using the Semliki Forest Virus expression. Cytotechnol. 1997;24:65–72
  30. Bennett CF, Chiang MY, Monia BP, Crooke ST. Regulation of 5-lipoxygenase and 5-lipoxygenase-activating protein expression in HL-60 cells. Biochem J. 1993;289:33–39
  31. Werz O, Schneider N, Brungs M, Sailer ER, Safayhi H, Ammon HPT. A test system for leukotriene synthesis inhibitors based on the in vitro differentiation of human leukemic cell lines HL-60 and Mono Mac 6. Naunyn-Schmiedebergs Arch Pharmacol. 1997;356:441–445
  32. Nahler G, Metelmann H, Sperber H. Treatment of gonartrosis with Zeel–results of a randomised, comparative clinical trial with hyaluronic acid. Orthopädische Praxis. 1996;32:354–359
  33. Maronna U, Weiser M, Klein P. Oral treatment of gonarthritis with Zeel–results of a double-blind equivalence study versus Diclofenac. Orthopaedische Praxis. 2000;36:285–291
  34. Altman R, Asch E, Bloch D. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum. 1986;29:1039–1049
  35. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis. Ann Rheum Dis. 1957;16:494–501
  36. Lequesne M. Klinische und röntgenologische Verlaufsbeobachtung bei Hüft und Kniearthrosen–Methoden und Ergebnisse. Z Rheumatol. 1994;243–249
  37. Stucki G, Meier D, Stucki S. Evaluation einer deutschen version des WOMAC-Arthroseindex [Evaluation of a German version of the WOMAC Arthrosis Index]. Z Rheumatol. 1996;55:40–49
  38. Birnesser H, Klein H-P, Weiser M. A modern homeopathic medication works as well as COX 2 inhibitors. Der Allgemeinarzt. 2003;25:261–264
  39. Richter M. Arthrose. Munich, Germany: PVG Pharmazeutische Verlagsgesellschaft mbH; 1983;
  40. Zenner S, Metelmann H. Praxiserfahrungen mit einem Homöopathischen Zäpfchenpräparat. Therapeuticon. 1991;5:63–68
  41. Müller-Krampe B, Gottwald R, Weiser M. Symtomatische behandlung von akuten fieberhaften infekten mit einem modernen homöopathikum [Symptomatic treatment of acute febrile infections with a modern homeopathic preparation]. Biol Med. 2002;31:79–85
  42. Ong KS, Seymour RA. Pain measurement in humans. Surgeon. 2004;2:15–27
  43. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312:1215–1218
  44. Derasse M, Klein H, Weiser M. The effects of homeopathic preparation Viburcol compared with acetaminophen in the symptomatic treatment of acute febrile infections in children: an observational pilot study. Explore (NY). 2005;1:33–39
  45. Feder G, Katz T. Randomised controlled trials for homoeopathy. BMJ. 2002;324:498–499
  46. Dollery CM, Owen CA, Sukhova GK, Krettek A, Shapiro SD, Libby P. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation. 2003;107:2829–2836
  47. Seyama Y, Wachi H. Atherosclerosis and matrix dystrophy. J Atheroscler Thromb. 2004;11:236–245
  48. Katayama K, Fujita T. Studies on biotransformation of elastase (III. Effects of elastase binding proteins in serum on the disappearance of 131 I-labeled elastase from blood). Biochim Biophys Acta. 1974;336:165–177
  49. Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M. Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med. 1999;131:409–416
  50. Vecchio PC. Attitudes to alternative medicine by rheumatology outpatient attenders. J Rheumatol. 1994;21:145–147
  51. Pioro-Boisset M, Esdaile JM, Fitzcharles MA. Alternative medicine use in fibromyalgia syndrome. Arthritis Care Res. 1996;9:13–17
  52. Arcury TA, Bernard SL, Jordan JM, Cook HL. Gender and ethnic differences in alternative and conventional arthritis remedy use among community-dwelling rural adults with arthritis. Arthritis Care Res. 1996;9:384–390
  53. Nicassio PM, Schuman C, Kim J, Cordova A, Weisman MH. Psychosocial factors associated with complementary treatment use in fibromyalgia. J Rheumatol. 1997;24:2008–2013

PII: S1550-8307(06)00452-6

doi: 10.1016/j.explore.2006.10.002

Explore: The Journal of Science and Healing
Volume 3, Issue 1 , Pages 16-22 , January 2007

Article Tools

* Image Usage & Resolution